Artia Global Partners’s Protagonist Therapeutics PTGX Stock Holding History

Artia Global Partners’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.42M	Sell	22,931 -20	-0.1%	-$1.77K	0.48%	34
2025 Q4	$2M	Hold	22,951	–	–	0.28%	38
2025 Q3	$1.52M	Hold	22,951	–	–	0.24%	39
2025 Q2	$1.27M	Sell	22,951 -310,900	-93%	-$14.9M	0.31%	29
2025 Q1	$16.1M	Buy	333,851 +40,000	+14%	+$1.68M	4.09%	8
2024 Q4	$11.3M	Buy	293,851 +169,411	+136%	+$7.39M	4.05%	14
2024 Q3	$5.6M	Hold	124,440	–	–	1.53%	13
2024 Q2	$4.31M	Hold	124,440	–	–	0.83%	17
2024 Q1	$3.6M	Buy	124,440 +12,100	+11%	+$329K	0.72%	19
2023 Q4	$2.58M	Hold	112,340	–	–	0.75%	17
2023 Q3	$1.87M	Hold	112,340	–	–	0.78%	19
2023 Q2	$3.1M	Buy	+112,340	New	+$2.81M	1.07%	22

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Artia Global Partners's PTGX Position: Q1 2026 in Review

Artia Global Partners reduced its Protagonist Therapeutics (PTGX) stake by 0.09% in Q1 2026, selling an estimated $1.77K and leaving 22,931 shares worth $2.42M. The position accounts for 0.48% of the portfolio, ranked #34.

Artia Global Partners first reported a position in PTGX in Q2 2023 and has held it in 12 quarters since. The position peaked at $16.1M in Q1 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Artia Global Partners held 22,931 shares of Protagonist Therapeutics worth $2.42M as of Q1 2026.
Artia Global Partners sold 20 Protagonist Therapeutics shares in Q1 2026, an estimated $1.77K.
Protagonist Therapeutics made up 0.48% of Artia Global Partners's portfolio in Q1 2026, its #34 holding.
Artia Global Partners first reported a position in Protagonist Therapeutics in Q2 2023 and has held it in 12 quarters since.
Artia Global Partners's Protagonist Therapeutics position peaked at $16.1M in Q1 2025.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Artia Global Partners's 13F filing for Q1 2026, filed 15 May 2026.